Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study.
暂无分享,去创建一个
A. Skene | J. Hampton | M. Morris | I. Ford | A. McMahon | W. Hillis | A. Clark | K. Fox | H. Dargie | J. Mcmurray | J. Birkhead | A. Trainer | A. Nears | M. Ford | H. Christie | C. Ferrell | B. Shaw | Diment | I. Grp
[1] P. Macfarlane,et al. Prognosis of angina with and without a diagnosis: 11 year follow up in the Whitehall II prospective cohort study , 2003, BMJ : British Medical Journal.
[2] A. McMahon,et al. Approaches to combat with confounding by indication in observational studies of intended drug effects , 2003, Pharmacoepidemiology and drug safety.
[3] J. McMurray,et al. The current cost of angina pectoris to the National Health Service in the UK , 2003, Heart.
[4] J. Kasprzak,et al. Predictors of long term outcome in medically treated patients with unstable angina. , 2003, The Canadian journal of cardiology.
[5] G. Dagenais,et al. Revisiting the Canadian Cardiovascular Society grading of stable angina pectoris after a quarter of a century of use. , 2002, The Canadian journal of cardiology.
[6] W. Hillis,et al. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.
[7] L. Campeau. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. , 2002, The Canadian journal of cardiology.
[8] D. Tanné,et al. Severity of Angina Pectoris and Risk of Ischemic Stroke , 2002, Stroke.
[9] A. McMahon,et al. Observation and experiment with the efficacy of drugs: a warning example from a cohort of nonsteroidal anti-inflammatory and ulcer-healing drug users. , 2001, American journal of epidemiology.
[10] F. Lampe,et al. Variability of angina symptoms and the risk of major ischemic heart disease events. , 2001, American journal of epidemiology.
[11] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[12] N. Wald,et al. When can a risk factor be used as a worthwhile screening test? , 1999, BMJ.
[13] J Marrugat,et al. Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. RESCATE Study Group. Resources Used in Acute Coronary Syndromes and Delays in Treatment. , 1999, The American journal of cardiology.
[14] K. Teo,et al. Long-term nitrate use in chronic coronary artery disease: need for a randomized controlled trial. , 1999, American heart journal.
[15] C Kawai,et al. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. , 1999, American heart journal.
[16] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[17] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[18] W. Kannel,et al. Epidemiologic assessment of angina before and after myocardial infarction: The Framingham study. , 1996, American heart journal.
[19] W. O’Neill,et al. A new clinical classification for hospital prognosis of unstable angina pectoris. , 1995, The American journal of cardiology.
[20] P. Bossuyt,et al. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. , 1995, Journal of the American College of Cardiology.
[21] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[22] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[23] J. Herlitz,et al. Occurrence of angina pectoris prior to acute myocardial infarction and its relation to prognosis. , 1993, European heart journal.
[24] C. Naylor,et al. The Canadian Cardiovascular Society Grading Scale for Angina Pectoris: Is It Time for Refinements? , 1992, Annals of Internal Medicine.
[25] H. Tunstall-Pedoe. Angina Pectoris: Epidemiology and Risk Factors , 1985 .
[26] F. Lampe,et al. Chest pain on questionnaire and prediction of major ischaemic heart disease events in men. , 1998, European heart journal.
[27] Gandhi Mm. Clinical epidemiology of coronary heart disease in the UK. , 1997 .